Annatto Tocotrienol may improve markers of liver health in people with NAFLD
Six hundred milligrams per day of the delta-tocotrienol supplement for 24 weeks resulted in significant reductions in liver enzymes, markers of oxidative stress, hepatic steatosis index, and HOMA-IR scores (a measure of insulin resistance), according to the study conducted at the Institute of Pathology of the Armed Forces in Pakistan.
Data published in Complementary therapies in medicineAlso reported that the placebo and tocotrienol groups had anthropometric values, such as weight, BMI, and waist circumference since both groups were assigned a low fat diet, but participants in the tocotrienol group experienced significantly greater reductions in all three measures, compared to placebo.
NAFLD is the most common liver defect in Western countries and parallels the epidemic of metabolic syndrome, obesity, and diabetes. Frequently disabling and occasionally leading to cirrhosis, fatty liver disease costs the U.S. health care system about $ 32 billion a year.
Forms of vitamin E
Vitamin E is a family of eight distinct but related molecules: four tocopherols (alpha, beta, gamma, delta) and four tocotrienols (alpha, beta, gamma, delta). Tocotrienols are derived from three main sources, including rice, palm and annatto.
The new study used annatto tocotrienols from DeltaGold, which do not contain tocopherol, and were made by US manufacturer American River Nutrition.
Commenting on the research, Dr. Barrie Tan, president of American River Nutrition, said: “While an earlier 12-week study already suggested significant benefits of DeltaGold for NAFLD patients, we now have evidence of a compelling benefit in terms of duration of response of tocotrienol for liver health.
“Doctors are currently recommending alpha-tocopherol supplementation for NAFLD patients with the goal of reducing oxidative stress, but we believe tocotrienol will be much more potent and go further to help. This is the subject of an ongoing 12-month clinical trial, which will compare the effects of alpha-tocopherol versus DeltaGold in NAFLD patients, and we look forward to sharing these results soon. “
For the new 24-week study, researchers recruited 71 people with NAFLD and randomly assigned them to receive either a placebo or tocotrienol DeltaGold (300 mg twice daily).
Results showed that liver enzymes (serum aminotransferases (ALT, AST)) decreased by 18-21% after 24 weeks in the tocotrienol group, while significant decreases in triglycerides (13%), malondialdehyde (MDA, marker oxidative stress: 19% reduction) and hs-CRP (21%) have also been reported.
The Fatty Liver Index (FLI), which includes measurements of weight, BMI, waist circumference, GGT and triglycerides, decreased by 15% after 24 weeks of DeltaGold supplementation.
Improvements in anthropometric measurements were also significantly greater in the tocotrienol group, with weight reductions of 6.8 kg (14.9 lbs) after 24 weeks, compared to 2.1 kg (4.6 lbs) in the placebo group. . In addition, BMI and waist circumference in the tocotrienol group decreased by 2.4 kg / m2 and 2.9 cm, respectively, compared to 0.7 kg / m2 and 1.15 cm in the placebo group. .
Looking at risk factors for metabolic syndrome, other measures at 24 weeks included HOMA-IR, adiponectin, and leptin. HOMA-IR, a stone that marks the presence and extent of insulin resistance, was reduced by 15% in the tocotrienol group.
Adiponectin and leptin are both hormones critically secreted by fatty tissue. Adiponectin regulates glucose levels and the breakdown of fatty acids, while leptin can be pro-angiogenic, pro-inflammatory, and chronically elevated in obesity. In the tocotrienol group, adiponectin levels increased by 44%, while leptin decreased by 18%. In comparison, adiponectin in the placebo group only increased by 3%, with leptin decreasing by 3%. IL-6 and TNF-alpha, also considered to be major inflammatory mediators of NAFLD and insulin resistance, were reduced by 24% and 21%, respectively, in the tocotrienol group.
“The present study demonstrated that delta-tocotrienol supplementation for 24 weeks effectively improved biochemical markers of hepatocellular damage and steatosis in patients with NAFLD”, write the researchers.
“Therefore, delta-tocotrienol could be considered as a therapeutic option in the management of patients with NAFLD.
“However, multicenter clinical trials are recommended to validate the results of the present study and to elucidate the molecular pathways and mechanisms of the actions of delta-tocotrienol in patients with NAFLD.”
Source: Complementary therapies in medicine
August 2020, Volume 52, 102494, doi: 10.1016 / j.ctim.2020.102494
“Delta-tocotrienol supplementation improves biochemical markers of hepatocellular damage and steatosis in patients with non-alcoholic fatty liver disease: a randomized, placebo-controlled trial”
Authors: MA Pervez et al.